Heart failure with preserved ejection fraction (HFpEF) is a complex condition that often develops in people with multiple other health problems, and is believed to arise from a network of related systemic processes. While existing protein biomarkers for HFpEF exhibit diagnostic limitations, a comprehensive protein analysis approach, known as proteomics, has the potential to improve […]
Alirocumab is an injectable PCSK9 inhibitor that reduces the level of low-density lipoprotein cholesterol (LDL-C), commonly known as “bad” cholesterol. The ODYSSEY OUTCOMES trial demonstrated that, among patients with a recent acute coronary syndrome (ACS) receiving high-intensity statin therapy, alirocumab reduced the risk of recurrent ischemic cardiovascular events and lowered all-cause mortality. Using ODYSSEY OUTCOMES […]
We are pleased to share the 2024 Canadian VIGOUR Centre (CVC) Annual Report, “Research in Motion“. Just as a Rube Goldberg machine transforms a simple action into a complex and interconnected chain reaction, research is a dynamic interplay of innovation, collaboration, and discovery. The CVC is committed to advancing cardiovascular research, recognizing that each step in the process drives […]
CSL112, a plasma-derived apolipoprotein A1, is a component of high-density lipoprotein cholesterol (HDL-C), also known as “good cholesterol”. CSL112 removes plaque from the arteries, and helps facilitate the removal process of low-density lipoprotein cholesterol (LDL-C), the “bad cholesterol”, from the body. The AEGIS-II trial found that CSL112 did not significantly reduce recurrent cardiovascular events compared […]
Cardiogenic shock (CS) is a life-threatening condition that occurs when the heart cannot pump enough blood and oxygen to the brain and other critical organs. While all CS patients experience low cardiac output and resulting end-organ hypoperfusion, data from registries and clinical trials reveal considerable variation in severity, underlying causes, volume status, and systemic vascular […]
Clinical trials in acute care settings, particularly those involving small populations or high mortality rates, face unique challenges in design and analysis. Co-authored by Drs. Fernando Zampieri and Justin Ezekowitz (University of Alberta), this review highlights innovative statistical methods and strategies to address these challenges, with an emphasis on cardiovascular therapies. The authors aim to guide researchers […]
Research from the STREAM-1 and STREAM-2 trials highlights the benefits of using half-dose tenecteplase, a clot-busting drug used to prevent death, for treating elderly patients (aged ≥75 years) with ST-segment elevation myocardial infarction (STEMI). STREAM-1 found that full-dose tenecteplase increased the risk of intracranial hemorrhage in this age group, while halving the dose eliminated this risk. STREAM-2 confirmed that […]
